{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:46:13Z","timestamp":1794707173240,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Polypharmacy (i.e., treatment with\u2009\u2265\u20095 drugs) is common in patients with atrial fibrillation (AF) and has been associated with suboptimal management and worse outcomes. Little is known about how prescribed drug patterns affect management and prognosis in patients with AF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Based on data from the prospective global GLORIA-AF Registry Phase III (recruiting patients with AF and CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score\u2009\u2265\u20091), we performed a latent class analysis to identify treatment patterns based on 14 drug classes including cardiovascular (CV) and non-CV drugs. We analysed associations with oral anticoagulant (OAC) use and risk of a composite primary outcome (all-cause death and major adverse cardiovascular events (MACE)) and secondary outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 21,245 patients (mean age\u00a070.2\u2009\u00b1\u200910.3 years, 44.9% females), we identified 6 patterns: i) Low Medicated pattern (18.3%); ii) Hypertension pattern (21.1%); iii) Heart Failure pattern (20.0%); iv) CV Prevention pattern (21.0%); v) Mixed Morbidity pattern (4.5%); and vi) High Medicated pattern (15.0%). All groups had higher odds of OAC use vs the Low Medicated pattern, with highest prevalences in the Heart Failure pattern (OR [95%CI]: 2.17 [1.90\u20132.48]) and the High Medicated pattern (OR [95%CI]: 2.08 [1.77\u20132.44]). Over 3-year follow-up, Heart Failure, Mixed Morbidity and High Medicated patterns were associated with higher risk of the primary composite outcome (aHR [95%CI]: 1.32 [1.14\u20131.53]; 1.45 [1.17\u20131.80] and 1.35 [1.14\u20131.60], respectively). Similar results were observed for all-cause mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In patients with AF, different treatment patterns can be identified. Each pattern was associated with unique OAC use and long-term clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-025-03858-w","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:19:56Z","timestamp":1737469196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patterns of pharmacological treatment in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF Registry Phase III"],"prefix":"10.1186","volume":"23","author":[{"given":"Bernadette","family":"Corica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Francesco","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Olshansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the GLORIA-AF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"3858_CR1","doi-asserted-by":"publisher","first-page":"100386","DOI":"10.1016\/j.lanepe.2022.100386","volume":"17","author":"J Wu","year":"2022","unstructured":"Wu J, Nadarajah R, Nakao YM, Nakao K, Wilkinson C, Mamas MA, et al. Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3\u00b74 million individuals. Lancet Regional Health Eur. 2022;17:100386.","journal-title":"Lancet Regional Health Eur"},{"key":"3858_CR2","doi-asserted-by":"crossref","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:1\u201310.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"3858_CR3","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/S2666-7568(24)00007-2","volume":"5","author":"K Nicholson","year":"2024","unstructured":"Nicholson K, Liu W, Fitzpatrick D, Hardacre KA, Roberts S, Salerno J, et al. Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. Lancet Healthy Longev. 2024;5:e287\u201396.","journal-title":"Lancet Healthy Longev"},{"key":"3858_CR4","doi-asserted-by":"publisher","first-page":"e001257","DOI":"10.1136\/openhrt-2020-001257","volume":"7","author":"C Gallagher","year":"2020","unstructured":"Gallagher C, Nyfort-Hansen K, Rowett D, Wong CX, Middeldorp ME, Mahajan R, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020;7:e001257.","journal-title":"Open Heart"},{"key":"3858_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Thromb Haemost. 2024;124:135\u201348.","journal-title":"Thromb Haemost"},{"key":"3858_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","volume":"20","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Vitolo M, Bonini N, Fawzy AM, Ding WY, et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 2022;20:326.","journal-title":"BMC Med"},{"key":"3858_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12875-019-0969-9","volume":"20","author":"M Guisado-Clavero","year":"2019","unstructured":"Guisado-Clavero M, Viol\u00e1n C, L\u00f3pez-Jimenez T, Roso-Llorach A, Pons-Vigu\u00e9s M, Mu\u00f1oz MA, et al. Medication patterns in older adults with multimorbidity: a cluster analysis of primary care patients. BMC Fam Pract. 2019;20:82.","journal-title":"BMC Fam Pract"},{"key":"3858_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamacardio.2017.4665","volume":"3","author":"T Inohara","year":"2018","unstructured":"Inohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, et al. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiol. 2018;3:54.","journal-title":"JAMA Cardiol"},{"key":"3858_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12916-024-03373-4","volume":"22","author":"GF Romiti","year":"2024","unstructured":"Romiti GF, Corica B, Mei DA, Bisson A, Boriani G, Olshansky B, et al. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the Prospective Global GLORIA-AF Registry. BMC Med. 2024;22:151.","journal-title":"BMC Med"},{"key":"3858_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00392-022-01996-2","volume":"111","author":"GYH Lip","year":"2022","unstructured":"Lip GYH, Kotalczyk A, Teutsch C, Diener H-C, Dubner SJ, Halperin JL, et al. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clin Res Cardiol. 2022;111:560\u201373.","journal-title":"Clin Res Cardiol"},{"key":"3858_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00392-021-01957-1","volume":"111","author":"MV Huisman","year":"2022","unstructured":"Huisman MV, Teutsch C, Lu S, Diener H-C, Dubner SJ, Halperin JL, et al. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clin Res Cardiol. 2022;111:548\u201359.","journal-title":"Clin Res Cardiol"},{"key":"3858_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","volume":"167","author":"MV Huisman","year":"2014","unstructured":"Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167:329\u201334.","journal-title":"Am Heart J"},{"key":"3858_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ahj.2019.08.012","volume":"218","author":"M Mazurek","year":"2019","unstructured":"Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. Am Heart J. 2019;218:123\u20137.","journal-title":"Am Heart J"},{"key":"3858_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i10","volume":"42","author":"DA Linzer","year":"2011","unstructured":"Linzer DA, Lewis JB. poLCA: An R Package for Polytomous Variable Latent Class Analysis. J Stat Softw. 2011;42:1\u201329.","journal-title":"J Stat Softw"},{"key":"3858_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0095798420930932","volume":"46","author":"BE Weller","year":"2020","unstructured":"Weller BE, Bowen NK, Faubert SJ. Latent Class Analysis: A Guide to Best Practice. J Black Psychol. 2020;46:287\u2013311.","journal-title":"J Black Psychol"},{"key":"3858_CR16","doi-asserted-by":"publisher","first-page":"15089","DOI":"10.1161\/JAHA.119.015089","volume":"9","author":"N Chen","year":"2020","unstructured":"Chen N, Alam AB, Lutsey PL, Maclehose RF, Claxton JS, Chen LY, et al. Polypharmacy, adverse outcomes, and treatment effectiveness in patients \u226575 with atrial fibrillation. J Am Heart Assoc. 2020;9:15089.","journal-title":"J Am Heart Assoc"},{"key":"3858_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40266-023-01028-2","volume":"40","author":"M Gosselin","year":"2023","unstructured":"Gosselin M, Talbot D, Simard M, Chiu YM, M\u00e9sidor M, Boiteau V, et al. Classifying Polypharmacy According to Pharmacotherapeutic and Clinical Risks in Older Adults: A Latent Class Analysis in Quebec. Canada Drugs Aging. 2023;40:573\u201383.","journal-title":"Canada Drugs Aging"},{"key":"3858_CR18","first-page":"2219","volume":"11","author":"C G\u00f3mez-G\u00f3mez","year":"2023","unstructured":"G\u00f3mez-G\u00f3mez C, Moya-Molina M\u00c1, Tey-Aguilera MJ, Flores-Azofra J, Gonz\u00e1lez-Caballero JL. Baseline Profiles of Drug Prescriptions Prior to Diagnosis of Mild Cognitive Impairment (MCI) Obtained by Latent Class Analysis (LCA), and Assessment of Their Association with Conversion to Dementia. Healthcare (Switzerland). 2023;11:2219.","journal-title":"Healthcare (Switzerland)"},{"key":"3858_CR19","doi-asserted-by":"publisher","first-page":"e030565","DOI":"10.1161\/JAHA.123.030565","volume":"12","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Proietti M, Corica B, Bonini N, Boriani G, Huisman MV, et al. Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF. J Am Heart Assoc. 2023;12:e030565.","journal-title":"J Am Heart Assoc"},{"key":"3858_CR20","doi-asserted-by":"crossref","unstructured":"Bucci T, Romiti GF, Ishiguchi H, Gerra L, Mantovani M, Huang B, et al. Adverse events in clinically complex elderly patients with atrial fibrillation according to oral anticoagulation status. EClinicalMedicine. 2024;78:102974.","DOI":"10.1016\/j.eclinm.2024.102974"},{"key":"3858_CR21","doi-asserted-by":"crossref","unstructured":"Brandes A, Pedersen SS, Hendriks JM. A call for action to include psychosocial management into holistic, integrated care for patients with atrial fibrillation. Europace. 2024;26:euae078.","DOI":"10.1093\/europace\/euae078"},{"key":"3858_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab303","volume":"24","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace. 2022;24:887\u201398.","journal-title":"Europace"},{"key":"3858_CR23","doi-asserted-by":"crossref","unstructured":"Vinter N, Cordsen P, Johnsen SP, Staerk L, Benjamin EJ, Frost L, et al. Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study. BMJ. 2024;385:e077209.","DOI":"10.1136\/bmj-2023-077209"},{"key":"3858_CR24","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.lanepe.2023.100596","volume":"28","author":"M Ding","year":"2023","unstructured":"Ding M, Ebeling M, Ziegler L, Wennberg A, Modig K. Time trends in atrial fibrillation-related stroke during 2001\u20132020 in Sweden: a nationwide, observational study. Lancet Regional Health Eur. 2023;28:100596.","journal-title":"Lancet Regional Health Eur"},{"key":"3858_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ehjqcco\/qcae007","volume":"10","author":"M Zuin","year":"2024","unstructured":"Zuin M, Malag\u00f9 M, Vitali F, Balla C, De Raffele M, Ferrari R, et al. Trends in atrial fibrillation-related mortality in Europe, 2008\u20132019. Eur Heart J Qual Care Clin Outcomes. 2024;10:467\u201378.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"3858_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ehjqcco\/qcac086","volume":"9","author":"K Teppo","year":"2023","unstructured":"Teppo K, Airaksinen KEJ, Jaakkola J, Halminen O, Linna M, Haukka J, et al. Trends in treatment and outcomes of atrial fibrillation during 2007\u201317 in Finland. Eur Heart J Qual Care Clin Outcomes. 2023;9:673\u20139.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"3858_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12916-021-02037-x","volume":"19","author":"J Kornej","year":"2021","unstructured":"Kornej J, Huang Q, Preis SR, Lubitz SA, Ko D, Murabito JM, et al. Temporal trends in cause-specific mortality among individuals with newly diagnosed atrial fibrillation in the Framingham Heart Study. BMC Med. 2021;19:170.","journal-title":"BMC Med"},{"key":"3858_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"3858_CR29","first-page":"20","volume":"122","author":"TF Chao","year":"2021","unstructured":"Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2021;122:20\u201347.","journal-title":"Thromb Haemost"},{"key":"3858_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","volume":"83","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. J Am Coll Cardiol. 2024;83:109\u2013279.","journal-title":"J Am Coll Cardiol"},{"key":"3858_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","volume":"20","author":"AD Elliott","year":"2023","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20:404\u201317.","journal-title":"Nat Rev Cardiol"},{"key":"3858_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: An integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627\u20138.","journal-title":"Nat Rev Cardiol"},{"key":"3858_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/a-1515-9630","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the \u201cAtrial Fibrillation Better Care\u201d Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb Haemost. 2022;122:406\u201314.","journal-title":"Thromb Haemost"},{"key":"3858_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","volume":"75","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75:1523\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"3858_CR35","doi-asserted-by":"publisher","first-page":"2140071","DOI":"10.1001\/jamanetworkopen.2021.40071","volume":"4","author":"Y Yao","year":"2021","unstructured":"Yao Y, Guo Y, Lip GYH. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events among Patients with Multimorbidity: The mAFA-II Randomized Clinical Trial. JAMA Netw Open. 2021;4:2140071.","journal-title":"JAMA Netw Open"},{"key":"3858_CR36","doi-asserted-by":"publisher","first-page":"24319","DOI":"10.1161\/JAHA.121.024319","volume":"11","author":"A Kotalczyk","year":"2022","unstructured":"Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH. Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry. J Am Heart Assoc. 2022;11:24319.","journal-title":"J Am Heart Assoc"},{"key":"3858_CR37","doi-asserted-by":"publisher","first-page":"e014932","DOI":"10.1161\/JAHA.119.014932","volume":"9","author":"M Proietti","year":"2020","unstructured":"Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the abc (Atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: A post hoc ancillary analysis from the affirm trial. J Am Heart Assoc. 2020;9:e014932.","journal-title":"J Am Heart Assoc"},{"key":"3858_CR38","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","volume":"73","author":"A Krishnaswami","year":"2019","unstructured":"Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2019;73:2584\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"3858_CR39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le CD, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827\u201334.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03858-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03858-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03858-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:20:12Z","timestamp":1737469212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03858-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3858"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03858-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. The study protocol was approved by local institutional review boards at each participating centre. The study was conducted according to the Good Clinical Practice and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. GB reports small speaker fees from Bayer, Boehringer Ingelheim, Boston, BMS, Daiichi, Sanofi, Janssen outside the submitted work. BO was US co-coordinator of GLORIA-AF Registry; TFC reported honoraria for lectures from Boehringer Ingelheim, Bayer, Pfizer, and Daiichi Sankyo, outside the submitted work. MVH has been receiving research grants from the Dutch Healthcare Fund, Dutch Heart Foundation, BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim and consulting fees from BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim to the institution. MP is investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871. GYHL has been consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are directly received personally. All the disclosures happened outside the submitted work. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU\u2019s Horizon Europe Research & Innovation programme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}